RAPT
Rapt Therapeutics Inc
NASDAQ · Biotechnology
$57.69
+0.01 (+0.02%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 545.80M | 533.51M | 481.00M |
| Net Income | 29.97M | 31.31M | 23.12M |
| EPS | — | — | — |
| Profit Margin | 5.5% | 5.9% | 4.8% |
| Rev Growth | +0.6% | -0.7% | +10.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 213.02M | 239.98M | 188.05M |
| Total Equity | 779.98M | 712.25M | 723.38M |
| D/E Ratio | 0.27 | 0.34 | 0.26 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 42.09M | 36.52M | 35.99M |
| Free Cash Flow | 24.22M | 23.20M | 21.80M |